- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02842073
An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
Assessing Changes in the Brain Melanocortin System and Sensory Processing in Response to Alcohol to Advance Our Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label Phase IIa pilot study of the tolerability and effects on binge drinking of bupropion and naltrexone for binge drinkers.
Participants: Investigators will recruit 12 men or women ages 21-34 years who exhibit a minimum of 5/3 (men/women) or more binge drinking episodes per month over the past three months. A binge drinking episode is defined as the consumption of 5/4 (men/women) standard drinks (~12 gms ethanol) in about a two hour period. Subjects may meet DSM-V criteria for mild or moderate alcohol use disorder. Subjects with overt physical dependence on alcohol, significant medical problems including seizures or bulimia, other substance use disorder except for occasional marijuana (based on toxicology screen) or significant psychiatric illness will be excluded.
Procedures (methods): As a first step in human trials investigators will give open label bupropion + naltrexone to active binge drinking subjects. The primary goal here is to assess tolerability and acceptability though changes in binge drinking and subjective sense of "effect" will be gathered as well. Investigators will also test cortical adaptation to binge drinking by completing tactile sensory testing and comparing the results to controls and individuals with overt physical dependence on alcohol. Investigators will recruit subjects using the e-mail listserve for UNC students, faculty and staff.
Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84. Subjects will be seen at screening and then at Weeks 0, 1, 3, 5, 8 and 12. Subjects will be breathalyzed and receive Medical Management counseling to encourage compliance and progress towards drinking goals. Investigators will use the Time Line Follow-Back approach to assess alcohol consumption history modified to include time taken to consume alcohol and define a binge. They will also measure craving for alcohol and will assess tolerability by probing for adverse effects. Key outcomes of interest include tolerability and acceptability, drinking behavior including frequency and intensity of binge drinking, and craving for alcohol. Because this is an open-label trial without a placebo comparison group no formal statistics will be completed and efficacy will not be assessed. Instead, this pilot study will inform investigators about the recruitment of binge drinkers, the tolerability and acceptability of bupropion/naltrexone in this population and potential efficacy signals.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between the ages of 21 and 34 years.
- A minimum of 5/3 (men/women) or more binge drinking episodes per month over the past three months. A binge drinking episode is defined as the consumption of 5/4 (men/women) standard drinks (~12 gms ethanol) in about a two hour period. Subjects may meet DSM-V criteria for mild or moderate alcohol use disorder.
- Ability to understand and sign written informed consent.
- Must have a 0.0 gms/dl breathalyzer reading on the day of screening and 0.0 gms/dl on the day of randomization.
- Must have a stable residence and be able to identify an individual who could contact participant if needed.
- Have a goal of sobriety or significantly reducing alcohol intake.
Exclusion Criteria
- Presence of physical dependence on alcohol as assessed by clear tolerance to alcohol or alcohol withdrawal symptoms based on SCID interview or a Severe Alcohol Use Disorder (>5 SCID DSM-V symptoms).
- Bupropion is contraindicated in individuals with a history of bulimia or a seizure disorder and naltrexone is contraindicated in acute liver disease and in patients using or misusing opioids.
- Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., renal insufficiency, cirrhosis, unstable hypertension, diabetes mellitus, seizure disorder). Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, anorexia/bulimia, severe depression, or suicidal ideation.
- Other substance abuse or dependence disorder other than nicotine or cannabis abuse.
- Concurrent use of anticonvulsants. Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception of stable doses of antidepressants for one month. Bupropion is commonly added to antidepressants for augmentation so the use of another antidepressant does not represent a safety concern. Prior history of adverse reaction to bupropion or naltrexone.
- AST or ALT > 3.5 times ULN or bilirubin > 1.5 X ULN.
- Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.
- Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal).
- Women who are breastfeeding.
- Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol problems.
- Participation in any clinical trial within the past 60 days that would have safety concerns for the trial.
- Court-mandated participation in alcohol treatment or pending incarceration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naltrexone and Buproprion
Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services.
Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
|
Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services.
Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services.
Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Associated Adverse Events
Time Frame: 12 weeks
|
Tolerability assessed by specifically probing for intervention-associated adverse effects.
|
12 weeks
|
Number of Participants Discontinuing Subsequent to Defined Intolerance
Time Frame: Throughout study, a total of approximately 12 weeks
|
Retention was evaluated indirectly by accounting for those participants who discontinued either naltrexone or bupropion or study participation itself due to intolerance.
|
Throughout study, a total of approximately 12 weeks
|
Number of Binge Drinking Days During Treatment
Time Frame: 12 weeks
|
The number of binge drinking days during treatment with bupropion + naltrexone
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Final Penn Alcohol Craving Scale (PACS) Score
Time Frame: 12 weeks
|
Craving for alcohol will be assessed using the Penn Alcohol Craving Scale (PACS) The PACS is a five-item self-administered instrument for assessing craving.
Frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking.
The final item asks the responder to provide an average rating of his/her craving over the course of the past week.
The questions on the PACS use descriptors coupled with numerical ratings ranging from 0 to 6 with the highest possible total score of 30.
Higher scores reflect a higher level of craving.
This outcome measure is the final PACS total score obtained in the trial.
|
12 weeks
|
Mean Number of Drinks/Binge Drinking Day During Treatment
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: James Garbutt, UNC Chapel Hill
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcohol Drinking
- Binge Drinking
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Narcotic Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Alcohol Deterrents
- Dopamine Uptake Inhibitors
- Naltrexone
- Bupropion
Other Study ID Numbers
- 16-1370
- TTSA018P1 (Other Identifier: NCTraCS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge Drinking
-
HBSARecruitingBinge Drinking, Underage Drinking, Drinking and Driving, Alcohol-Related HarmsUnited States
-
Mayo ClinicJames and Esther King Biomedical Research ProgramCompletedfor Cigarette Smoking and Binge Drinking CessationUnited States
-
University of North Carolina, Chapel HillAgency for Healthcare Research and Quality (AHRQ)CompletedAlcohol Use Disorder | Drinking, Alcohol | Drinking Excessive | Risky Health Behavior | Drinking, BingeUnited States
-
University of Southern CaliforniaNot yet recruitingBinge Drinking | Binge Eating
-
Pacific Institute for Research and EvaluationKlein Buendel, Inc.CompletedAggression | Drug Use | Peer Group | Drink Too Much | Drink Driving | Drinking, Binge | Drunk | Aggression SexualUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedTobacco Use Cessation | Adherence | Alcohol & Drug Use | Nicotine Transdermal SystemUnited States
-
Centre Hospitalier Universitaire, AmiensEPSM Marne, Reims; SCA-LAB UMR-CNRS 9193, Lille; Paul Valery University, MontpellierRecruitingAlcohol Drinking | Binge DrinkingFrance
-
University of MinhoFoundation for Science and Technology (FCT)Recruiting
-
University Hospital, CaenRecruitingAlcohol Drinking | Binge DrinkingFrance
-
University of MinhoCompletedBinge DrinkingPortugal
Clinical Trials on Naltrexone
-
San Diego State UniversityRecruitingPlacebo | NaltrexoneUnited States
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem DrinkingUnited States
-
Alkermes, Inc.Terminated
-
Alkermes, Inc.Completed
-
Alkermes, Inc.Completed
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...CompletedOpioid-Related Disorders | Heroin DependenceUnited States, Russian Federation
-
Centre for Addiction and Mental HealthUnknown
-
Drug Delivery Company, LLC DBA Akyso PharmaceuticalsNational Institute on Drug Abuse (NIDA); Laboratory Corporation of America; Cognitive...Not yet recruiting
-
State University of New York - Upstate Medical...CephalonCompletedAlcohol Dependence | Schizophrenia | Schizoaffective Disorders | Bipolar DisordersUnited States
-
Medical University of LublinRecruitingQuality of Life | Vulvodynia | NaltrexonePoland